By Sriparna Roy

(Reuters) -The U.S. Food and Drug Administration has approved Otsuka’s injectable drug to treat patients with a potentially life-threatening kidney disease, the health regulator’s website showed on Tuesday.

The drug, branded as Voyxact, was approved to reduce proteinuria in patients with primary immunoglobulin A nephropathy, which causes inflammation in the kidneys and can eventually lead to the organ’s failure.

The company did not immediately respond to Reuters’ request for comment on pricing and availability.

Voyxact is a monoclonal antibody designed to be administered every four weeks, either through a caregiver or by the patient, providing the option of at-home convenience.

IgAN, also called Berger’s disease, occurs when a type of antibodies called immunoglobulin A

See Full Page